Cybin Inc.

Equities

CLXPF

CA23256X4075

Real-time Estimate Cboe BZX Other stock markets 02:19:41 2024-12-09 pm EST			5-day change	1st Jan Change
10.48 ^USD	-3.01%		+5.35%	-32.38%

Nov. 18	Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	MT
Nov. 18	Cybin Inc. - Special Call

Presentation Operator MessageOperator (Operator)Good morning...

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Cybin Inc.

Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	Nov. 18	MT
Cybin Inc. - Special Call	Nov. 18
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder	Nov. 18	CI
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 13	CI
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results	Nov. 13	CI
Cybin Inc. - Special Call	Oct. 08
Cybin Inc. Announces Executive Appointments	Oct. 01	CI
Cybin Inc.(NYSEAM:CYBN) added to S&P Global BMI Index	Sep. 22	CI
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones	Sep. 20	CI
Cybin Inc. - Shareholder/Analyst Call	Aug. 27
Cybin to Begin Phase 3 Trial of Treatment for Major Depressive Disorder This Summer	Aug. 13	MT
Cybin Inc. Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder	Aug. 13	CI
Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee	Aug. 13	CI
Cybin Inc. Reports Earnings Results for the First Quarter Ended June 30, 2024	Aug. 08	CI
Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Jun. 26	CI
Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	Jun. 11	CI
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	May. 06	CI
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	Apr. 17	MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	Apr. 16	MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors	Mar. 18	CI
Sector Update: Health Care Stocks Softer Friday Afternoon	Mar. 15	MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	Mar. 15	MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	Mar. 15	CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	Mar. 14	MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	Mar. 14	CI